MAI Capital Management
LYEL icon

MAI Capital Management’s Lyell Immunopharma LYEL Stock Holding History

MAI Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$2.01K – 3596
2026
Q1 		$2.01K Hold
100
– – ﹤0.01% 3924
2025
Q4 		$3.08K Hold
100
– – ﹤0.01% 3298
2025
Q3 		$1.62K Hold
100
– – ﹤0.01% 3358
2025
Q2 		$884 Hold
100
– – ﹤0.01% 3651
2025
Q1 		$1.08K Hold
100
– – ﹤0.01% 3114
2024
Q4 		$1.28K Buy
+100
New +$1.98K ﹤0.01% 3134

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

MAI Capital Management's LYEL Position: Q2 2026 in Review

MAI Capital Management sold out of Lyell Immunopharma (LYEL) in Q2 2026, closing a stake of 100 shares — an estimated $2.01K sold.

MAI Capital Management first reported a position in LYEL in Q4 2024 and held it in 6 quarters. The position peaked at $3.08K in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • MAI Capital Management reported no remaining Lyell Immunopharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 100 Lyell Immunopharma shares in Q2 2026, an estimated $2.01K.
  • MAI Capital Management first reported a position in Lyell Immunopharma in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Lyell Immunopharma position peaked at $3.08K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.